COGT vs. IMNM, AYTU, TGTX, MRUS, XENE, BHVN, IDYA, FOLD, RYTM, and ACAD
Should you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Immunome (IMNM), Aytu BioPharma (AYTU), TG Therapeutics (TGTX), Merus (MRUS), Xenon Pharmaceuticals (XENE), Biohaven (BHVN), IDEAYA Biosciences (IDYA), Amicus Therapeutics (FOLD), Rhythm Pharmaceuticals (RYTM), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical preparations" industry.
Cogent Biosciences (NASDAQ:COGT) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, community ranking, dividends, analyst recommendations and institutional ownership.
Immunome has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.
In the previous week, Immunome had 4 more articles in the media than Cogent Biosciences. MarketBeat recorded 9 mentions for Immunome and 5 mentions for Cogent Biosciences. Immunome's average media sentiment score of 0.84 beat Cogent Biosciences' score of 0.38 indicating that Immunome is being referred to more favorably in the news media.
44.6% of Immunome shares are held by institutional investors. 5.9% of Cogent Biosciences shares are held by insiders. Comparatively, 8.6% of Immunome shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Cogent Biosciences currently has a consensus target price of $14.67, indicating a potential upside of 54.06%. Immunome has a consensus target price of $29.80, indicating a potential upside of 80.50%. Given Immunome's stronger consensus rating and higher probable upside, analysts clearly believe Immunome is more favorable than Cogent Biosciences.
Cogent Biosciences received 251 more outperform votes than Immunome when rated by MarketBeat users. Likewise, 70.84% of users gave Cogent Biosciences an outperform vote while only 70.27% of users gave Immunome an outperform vote.
Cogent Biosciences has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500. Comparatively, Immunome has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500.
Cogent Biosciences has a net margin of 0.00% compared to Immunome's net margin of -1,829.44%. Immunome's return on equity of -37.33% beat Cogent Biosciences' return on equity.
Summary
Immunome beats Cogent Biosciences on 13 of the 17 factors compared between the two stocks.
Get Cogent Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cogent Biosciences Competitors List
Related Companies and Tools
Free COGT Stock Alerts